BioSpace News Archive

The report carefully investigates the present market scenario and the fundamental growth prospects. The report entails an organized database of the Pharmaceutical Packaging market dynamics that helps market analysts estimate the global market growth rate over the projected timeline.

Proscia®, the leader in digital and computational pathology solutions, and Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems, today announced a collaboration to accelerate digital pathology adoption at an enterprise scale.

Accord BioPharma announced the hire of several key members of its leadership team: George Esgro Jr. as Senior Vice President of Commercial Operations; Kayla Williams as Executive Director of U.S. Portfolio Strategy and Commercial Development; Nuvan Dassanaike as Senior Vice President of Digital and Marketing Strategy & Operations; and Paul Purdy as Vice President and Head of Market Access.

Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced that it has closed on $12 million in convertible notes with both existing and new investors.

In the last few years, there’s been an increasing demand for economical and disposable medical device packaging solutions in the majority of countries, which has acted as the major factor driving the growth of the global medical device packaging market.

Tevard Biosciences, the pioneer of tRNA-based treatments for severe genetic diseases, today announced the appointment of Paul Schimmel, Ph.D., Susan Ackerman, Ph.D., and Nicholas Ingolia, Ph.D., to its scientific advisory board.

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced that following the review of its research and corporate activities, the Company is taking steps to streamline its clinical, research and development, and administrative operations in order to reduce costs.

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.

Sensei Biotherapeutics, Inc., an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, announced the appointment of William Ringo, MBA, as chair of its Board of Directors.

Ardelyx, Inc. announced that on March 4, 2022, the compensation committee of the company’s board of directors granted ten new non-executive employees options to purchase an aggregate of 105,470 shares of the company’s common stock, and granted an aggregate of 71,250 Restricted Stock Units to eleven new non-executive employees.